- Still waiting to go public with its initial public offering (IPO) at tech-intensive KOSDAQ later this year, Genome & Company laid out the biotech firm's various business models and oncoming visions focusing on its microbiome-based immuno-oncology expertise at its IR event on Thursday.
- Founded back in 2015, the bio company has strong line-ups in discovering and developing innovative therapeutics in immuno-oncology, ma....
Tags : Genome & company, Microbiome R&D, top microbiome Biotech Company, kosdaq, konex,
Markets
4 Min read
MICROBIOME BIOTECH FIRM GENOME & COMPANY AWAIT FINAL WORD BEFORE IPO ON KOSDAQ
Published On 03 Dec 2020 10:28 AM
comments (0)